Location of ryanodine receptor type 2 mutation predicts age of onset of sudden death in catecholaminergic polymorphic ventricular tachycardia. A systematic review and meta analysis of case based literature
Halil BeqajiD, Leah R. SittenfeldiD, Alex R. ChangiD, Marco MiottoiD, Haikel DridiiD, Gloria WillsoniD, Carolyn Martinez JorgeiD, Jaan Altosaar LiiD, Steven R. ReikeniD, Yang LiuiD, Zonglin Dai, Andrew R. MarksiD
Abstract
BackgroundCatecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited arrhythmia caused by mutations in the ryanodine receptor type 2 (RyR2). Diagnosis of CPVT often occurs after a major cardiac event, thus posing a severe threat to the patients health. MethodsPublication databases, including PubMed, Scopus, and Embase, were searched for articles on patients with RyR2-CPVT mutations and their associated clinical presentation. Articles were reviewed by two independent reviewers and mutations were analyzed for demographic information, mutation distribution, and therapeutics. The human RyR2 cryo-EM structure was used to model CPVT mutations and predict the diagnosis and outcomes of CPVT patients. FindingsWe present a database of 1008 CPVT patients from 227 papers. Data analyses revealed that patients most often experienced exercise-induced syncope in their early teenage years but the diagnosis of CPVT took a decade. Mutations located near key regulatory sites in the channel were associated with earlier onset of CPVT symptoms including sudden cardiac death. InterpretationThe present study provides a road map for predicting clinical outcomes based on the location of RyR2 mutations in CPVT patients. The study was partially limited by the inconsistency in the depth of information provided in each article, but nevertheless is an important contribution to the understanding of the clinical and molecular basis of CPVT and suggests the need for early diagnosis and creative approaches to disease management. FundingThe work was supported by grant NIH R01HL145473, P01 HL164319 R25HL156002, T32 HL120826.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Redefining catecholaminergic polymorphic ventricular tachycardia (CPVT) as a neurocardiac condition
Molly O’Reilly, Arie O. Verkerk, Carol Ann Remme·bioRxiv·Jan 27, 2025
- Enhanced CICR activity reduces ER Ca2+ level in cells expressing CPVT-linked mutant RyR2
N. Kurebayashi, T. Murayama, … T. Sakurai·bioRxiv·Jan 16, 2021
- A Novel Mice Model of Catecholaminergic Polymorphic Ventricular Tachycardia Generated by CRISPR/Cas9
Cuilan Hou, Xunwei Jiang, … Tingting Xiao·bioRxiv·Oct 14, 2021
- CaMKII Phosphorylation of RyR2 is Essential for Arrhythmia in CPVT
Sofia De La Serna Buzón, Xiaoting Wang, … Vassilios J. Bezzerides·bioRxiv·Sep 15, 2025
- Calmodulin mutation N54I causes autosomal dominant CPVT in mice
Daniel J. Blackwell, Nieves Gómez‐Hurtado, … Björn C. Knollmann·bioRxiv·Sep 18, 2026
- Structural Evaluation of RYR2-CPVT Missense Variants and Continuous Bayesian Estimates of their Penetrance
Kohei Yamauchi, Matthew Ku, … Brett M. Kroncke·medRxiv·Mar 20, 2025